These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28442915)

  • 21. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
    Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
    J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
    Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
    Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
    Wei X; Zhao J; Yang L
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
    Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
    Perazzo H; Jorge MJ; Silva JC; Avellar AM; Silva PS; Romero C; Veloso VG; Mujica-Mota R; Anderson R; Hyde C; Castro R
    BMC Gastroenterol; 2017 Nov; 17(1):119. PubMed ID: 29169329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection.
    Babatin MA; Alghamdi AS; Albenmousa A; Alaseeri A; Aljarodi M; Albiladi H; Alsahafi A; Almugharbal M; Alothmani HS; Sanai FM; Bzeizi KI
    J Clin Gastroenterol; 2018; 52(5):452-457. PubMed ID: 28767462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?
    Zarębska-Michaluk D; Flisiak R; Jaroszewicz J; Janczewska E; Czauż-Andrzejuk A; Berak H; Horban A; Staniaszek A; Gietka A; Tudrujek M; Tomasiewicz K; Dybowska D; Halota W; Piekarska A; Sitko M; Garlicki A; Orłowska I; Simon K; Belica-Wdowik T; Baka-Ćwierz B; Mazur W; Białkowska J; Socha Ł; Wawrzynowicz-Syczewska M; Laurans Ł; Deroń Z; Lorenc B; Dobracka B; Tronina O; Pawłowska M
    J Interferon Cytokine Res; 2018 Feb; 38(2):93-100. PubMed ID: 29443655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
    Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
    J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
    Tasavon Gholamhoseini M; Sharafi H; Hl Borba H; Alavian SM; Sabermahani A; Hajarizadeh B
    BMJ Open; 2022 Jun; 12(6):e058757. PubMed ID: 35676019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of antiviral therapy for HCV on lipid levels.
    Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
    Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
    Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
    Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.